Evolus Business Summary

Evolus, Inc. (EOLS) operates as a performance beauty company primarily generating revenue through the direct sale of aesthetic products to healthcare providers in the cash-pay market. Its business is bifurcated into two core segments: injectable neurotoxins, led by its flagship product Jeuveau (prabotulinumtoxinA-xvfs), and hyaluronic acid (HA) dermal fillers, marketed under the Evolysse brand in the U.S. and Estyme in Europe. The company utilizes a digital-first commercial model and a loyalty-driven consumer rewards program to bypass traditional pharmaceutical reimbursement complexities, targeting a younger demographic of aesthetic patients. Evolus competes directly with industry titans AbbVie (Botox), Galderma (Dysport), Merz Aesthetics (Xeomin), and Revance Therapeutics (Daxxify). Within this landscape, Evolus positions itself as a high-growth disruptor, leveraging a lean, aesthetics-only focus to capture market share from diversified conglomerates by offering competitive pricing and a specialized portfolio. Founded in 2012 as a subsidiary of Alphaeon Corporation, Evolus is currently led by President and CEO David Moatazedi, who previously served as Senior Vice President and head of U.S. Medical Aesthetics at Allergan (the makers of Botox). The executive team was further strengthened in September 2025 with the appointment of Tatjana Mitchell as Chief Financial Officer, bringing extensive capital allocation experience from her tenure as a finance executive at Experian. Dr. Rui Avelar serves as the Chief Medical Officer and Head of R&D, overseeing the clinical expansion of the Evolysse filler line. The company’s strategic direction is guided by a board chaired by Vikram Malik and includes notable members such as Albert G. White III, President and CEO of CooperCompanies. Evolus maintains a strong institutional investor base, with significant positions held by BlackRock, The Vanguard Group, and specialized healthcare funds including Nantahala Capital Management and Tang Capital Management.